<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224260</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-011</org_study_id>
    <nct_id>NCT03224260</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese
      participants after multiple doses are administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">November 7, 2017</completion_date>
  <primary_completion_date type="Actual">November 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Death</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Measured by investigator assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Measured by investigator assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) Leading to Discontinuation of Study Therapy</measure>
    <time_frame>17 days</time_frame>
    <description>Measured by investigator assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) Resulting in Clinically Significant Bleeding</measure>
    <time_frame>17 days</time_frame>
    <description>Measured by investigator assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs (heart rate, systolic blood pressure, diastolic blood pressure, respiration rate, and temperature)</measure>
    <time_frame>17 days</time_frame>
    <description>Measured by investigator assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in electrocardiogram findings (ECGs)</measure>
    <time_frame>17 days</time_frame>
    <description>Measured by investigator assessment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 50 mg BMS-986177 once daily or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 200 mg BMS-986177 once daily or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 500 mg BMS-986177 once daily or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177</intervention_name>
    <description>Oral Suspension</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matched Placebo</intervention_name>
    <description>Oral Suspension</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be first-generation Japanese (born in Japan and not living outside
             of Japan for &gt; 10 years; both parents must be ethnically Japanese)

          -  Body Mass Index 18.0 to 25.0 kg/m2, inclusive

          -  Women must not be of nonchildbearing potential (cannot become pregnant)

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of allergy to BMS-986177 or other factor Xia inhibitors and/or formulation
             excipients or history of any significant drug allergy (such as anaphylaxis or
             hepatotoxicity)

          -  History or evidence of abnormal bleeding or coagulation disorder

        Other protocol defined inclusion and exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/safety/recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

